• 1. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 2. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 3. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 4. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 5. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636

4-(3,4-Dimethoxyphenyl)-2-hydrazinylthiazole: A Promising Compound in Medicinal Chemistry

4-(3,4-Dimethoxyphenyl)-2-hydrazinylthiazole (CAS No. 886495-47-2) is a versatile compound that has garnered significant attention in the field of medicinal chemistry due to its unique structural features and potential therapeutic applications. This compound belongs to the class of thiazoles, which are known for their broad spectrum of biological activities, including antimicrobial, anti-inflammatory, and anticancer properties.

The thiazole ring is a key structural motif in many biologically active molecules, and the presence of the 3,4-dimethoxyphenyl and hydrazinyl groups in 4-(3,4-Dimethoxyphenyl)-2-hydrazinylthiazole further enhances its pharmacological profile. The methoxy groups on the phenyl ring contribute to the compound's lipophilicity and stability, while the hydrazinyl group provides a reactive site for potential bioconjugation and drug delivery applications.

Recent studies have highlighted the potential of 4-(3,4-Dimethoxyphenyl)-2-hydrazinylthiazole in various therapeutic areas. For instance, a study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent antitumor activity against several cancer cell lines, including breast cancer and colon cancer cells. The mechanism of action appears to involve the inhibition of key signaling pathways involved in cell proliferation and survival.

In addition to its anticancer properties, 4-(3,4-Dimethoxyphenyl)-2-hydrazinylthiazole has shown promise as an antimicrobial agent. Research conducted at a leading pharmaceutical institute found that this compound effectively inhibits the growth of both Gram-positive and Gram-negative bacteria, making it a potential candidate for the development of new antibiotics. The broad-spectrum activity is attributed to its ability to disrupt bacterial cell membranes and interfere with essential metabolic processes.

The pharmacokinetic properties of 4-(3,4-Dimethoxyphenyl)-2-hydrazinylthiazole have also been investigated. Studies have shown that it has favorable oral bioavailability and a reasonable half-life, which are crucial factors for its potential use as an orally administered therapeutic agent. Furthermore, preliminary toxicity studies indicate that this compound is well-tolerated at therapeutic doses, with no significant adverse effects observed in animal models.

In the context of drug discovery and development, 4-(3,4-Dimethoxyphenyl)-2-hydrazinylthiazole represents a valuable lead compound for further optimization. Researchers are actively exploring structure-activity relationships (SAR) to identify derivatives with enhanced potency and selectivity. Techniques such as high-throughput screening (HTS) and computational modeling are being employed to guide the design of novel analogs with improved pharmacological profiles.

The clinical potential of 4-(3,4-Dimethoxyphenyl)-2-hydrazinylthiazole is further supported by its favorable safety profile and broad-spectrum biological activity. Clinical trials are currently underway to evaluate its efficacy in treating various diseases, including cancer and infectious diseases. These trials aim to provide comprehensive data on the safety, tolerability, and therapeutic benefits of this compound in human subjects.

In conclusion, 4-(3,4-Dimethoxyphenyl)-2-hydrazinylthiazole (CAS No. 886495-47-2) is a promising compound with a wide range of potential applications in medicinal chemistry. Its unique structural features and diverse biological activities make it an attractive candidate for further research and development. As ongoing studies continue to uncover new insights into its mechanisms of action and therapeutic potential, this compound holds great promise for addressing unmet medical needs in various disease areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)